Group 1 - The company has completed the registration of business changes and obtained a new business license from the Zhejiang Provincial Market Supervision Administration [2] - The company held its 2024 annual general meeting on May 16, 2025, where it approved the profit distribution and capital reserve conversion plan for 2024, which was implemented on June 6, 2025 [1] - The company held its second extraordinary general meeting of 2025 on June 4, 2025, where it approved the cancellation of the supervisory board, expansion of business scope, and amendments to the articles of association [2] Group 2 - The company's registered capital is 149,333,334 yuan, and its business scope includes various technical services, medical device sales, and electronic component manufacturing [2] - The company is classified as a listed other joint-stock company with a unified social credit code of 9133010079969193XF [2] - The company’s business activities encompass a wide range of sectors, including technology development, medical equipment, and electronic products [2]

股票代码：688767 证券简称：博拓生物 公告编号：2025-035 杭州博拓生物科技股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"）于2025年5月16日召开2024 年年度股东大会，审议通过了《关于2024年年度利润分配及资本公积转增股本预案的议 案》，权益分派已于2025年6月6日实施完毕。具体内容详见公司于2025年5月30日在上 海证券交易所网站（www.sse.com.cn）披露的《杭州博拓生物科技股份有限公司2024 年年度权益分派实施公告》（公告编号：2025-031）。 1 产租赁；园区管理服务；货物进出口；技术进出口；工程和技术研究和试验发展；计算 机软硬件及外围设备制造；信息技术咨询服务；电子真空器件制造；信息安全设备销售； 电子元器件零售；电子真空器件销售；电力电子元器件销售；信息安全设备制造；第二 类医疗设备租赁；计算器设备销售；电力电子元器件制造；电子元器件制造；电子专用 材料制造；集成电路 ...

Group 1 - A total of 24 companies were investigated by institutions on June 25, with 17 companies specifically targeted by funds [1][2] - The most popular company among funds was Botao Bio, which had 21 participating funds, followed by Sanfu Outdoor and Entropy Technology with 7 and 6 funds respectively [1][2] - The companies investigated belong to 12 different industries, with the textile and apparel, and pharmaceutical and biotechnology sectors having the most companies, each with 3 stocks listed [1] Group 2 - Among the companies investigated, 3 had a total market capitalization exceeding 50 billion yuan, while 13 had a market cap below 10 billion yuan [1] - In terms of market performance, 9 stocks among the investigated companies saw an increase in the last 5 days, with Haike Xinyuan, Bai'ao Intelligent, and Ganfeng Lithium leading with increases of 50.83%, 10.42%, and 5.88% respectively [1][2] - Conversely, 8 stocks experienced declines, with Mankalon, Botao Bio, and China Merchants Energy showing the largest drops of 7.94%, 5.35%, and 4.76% respectively [1][2]

Summary of the Conference Call on Botao Bio Industry Overview - **Industry**: Brain-Computer Interface (BCI) Technology - **Company**: Botao Bio - **Investment**: Acquired a 5% stake in Qingchuang Vision, a brain-computer interface company focused on depression treatment, leveraging technology from Zhejiang University [2][3] Key Points and Arguments - **Strategic Shift**: Botao Bio aims to transition from diagnostics to integrated diagnosis and treatment, particularly in the BCI sector [2][4] - **Government Support**: The Chinese government has prioritized BCI technology, allocating over 30 billion for development by 2030, with an additional 16.8 billion planned for the coming years [2][5] - **Market Potential**: The BCI technology market is vast, with over 1 billion patients suffering from major brain diseases in China, including nearly 100 million with depression [3][15] - **Technological Distinction**: BCI technology is categorized into invasive (high signal quality, up to 50 kHz) and non-invasive (lower signal quality) methods, with applications in rehabilitation and treatment of severe brain diseases [2][7][9] - **Research Landscape**: BCI research is primarily conducted in universities and research institutions, with leading companies like Zhiruan and Xingdao at the forefront [10] Additional Important Content - **Clinical Applications**: Current applications of BCI technology include rehabilitation for motor functions and sensory restoration, with significant room for growth in treating major brain diseases [9][15] - **Challenges in Development**: Invasive BCI technology faces high barriers due to its interdisciplinary nature, requiring collaboration across fields such as computer science, materials science, and clinical medicine [13] - **Unique Technologies**: Botao Bio has developed three core technologies for depression treatment, focusing on precise implantation, real-time emotional state monitoring, and closed-loop stimulation adjustment [19] - **Collaborations**: The company has established partnerships with Zhejiang University’s affiliated hospitals for clinical trials and research [21] - **Future Directions**: Plans for product development include a second-generation device with self-developed chips, aiming for clinical trials and eventual market release by 2029 [24][28] Market Dynamics - **DBS System Comparison**: Botao Bio's deep brain stimulation (DBS) system is designed to record, stimulate, and compute, differentiating it from existing products in the market [27] - **Patient Acceptance**: There is a high demand for new therapies among treatment-resistant depression patients, indicating a favorable market environment for innovative solutions [29] - **Regulatory Landscape**: The company anticipates regulatory approval for its DBS system by 2029, with a focus on personalized treatment approaches [28] Conclusion - **Investment Opportunity**: The BCI sector, particularly in depression treatment, presents significant investment potential driven by government support, technological advancements, and a large patient population in need of innovative therapies [2][5][15]

微流控产品打开增量市场，战略布局脑机接口。公司自研的微流控免疫荧光分析系统结合了精准与便 携，具有灵敏度高（可定量检测）、多项目同时检测、操作简单及性价比高等优点，差异化优势有望填 补化学发光难以覆盖市场的空白以及可部分替代免疫荧光检测市场。目前部分心肌标志物检测系列产品 已取得CE 注册备案，我们预计26 年开始贡献收入。此外，公司结合自身资金储备优势，战略布局脑机 接口优质公司-青石永隽，该公司为南湖脑机交叉研究院孵化的首个项目，由浙江大学侵入式脑机接口 团队核心成员创办，基础科学研究扎实。首款产品主要针对难治的重症抑郁症患者，全球抑郁症患者中 重症难治抑郁症患者约占30%，市场潜力较大。 投资建议：我们预计公司2025-2027 年实现营业收入6.02/7.52/9.16 亿元，归母净利润 1.47/1.83/2.24 亿 元。2025-2027 年对应PE 分别为32.10/25.68/20.99 倍。首次覆盖，给予公司"推荐"评级。 风险提示：新品研发及注册不及预期风险、核心产品竞争格局恶化风险、地缘政治导致政策波动风险 等。 深耕POCT 赛道，公司是全球产品布局最齐全的企业之一。公司成立于200 ...

Group 1 - The company held its second extraordinary general meeting of shareholders on June 4, 2025, to elect the fourth board of directors, which includes three non-independent directors and three independent directors, along with one employee representative director [1][2] - The newly elected board of directors will serve a term of three years starting from the date of the meeting [1] - Chen Yinlong was elected as the chairman of the fourth board of directors, and various specialized committees were established, including the Strategy Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee [2] Group 2 - The company appointed Wu Shujing as the general manager and Chen Yujie, Ye Chunsheng, and Liu Chao as vice general managers, with Fei Qijun appointed as the vice general manager and board secretary, and Yu Miaomiao as the financial officer [3][4] - All appointed senior management personnel meet the qualifications required for their positions and comply with relevant laws and regulations [4][7] - Huang Yufeng was appointed as the securities affairs representative to assist the board secretary [3][4] Group 3 - The third board of directors' independent director Wang Wenming and non-independent director Gao Hongmei will no longer serve after the completion of the board transition [5] - The company will no longer have a supervisory board, and its functions will be assumed by the audit committee of the board of directors [5]

Meeting Details - The shareholders' meeting of Hangzhou Botao Biological Technology Co., Ltd. was held on June 4, 2025 [1] - The meeting took place at a designated location in Hangzhou [1] - A total of 43 ordinary shareholders attended, holding 49,053,096 voting rights, which represents 45.9872% of the company's total voting rights [1] Voting Results - All non-cumulative voting proposals were approved, with 99.9035% of votes in favor, 0.0877% abstaining, and 0.0088% against [1] - The cumulative voting results included the election of Chen Yinlong, Chen Yujie, and Wu Shujian as non-independent directors, with their respective votes confirming their election [2] Independent Directors Election - Wang Liang and Duan Jianping were elected as independent directors of the fourth board [2] - The voting for these independent directors also met the required thresholds for approval [2] Legal Compliance - The meeting's convening and proceedings were confirmed to comply with legal and regulatory requirements, ensuring the legitimacy of the participants and voting processes [3]

Core Viewpoint - The legal opinion letter from Zhejiang Tiance Law Firm confirms the legality and validity of the procedures and results of the second extraordinary general meeting of shareholders for Hangzhou Botao Biotechnology Co., Ltd. in 2025 [1][11]. Group 1: Meeting Procedures - The meeting was convened following the approval of the board of directors on May 19, 2025, and the notice was published on May 20, 2025, on the Shanghai Stock Exchange and other platforms [2][3]. - The meeting is scheduled for June 4, 2025, at 14:00, with specific voting times for online participation [3]. Group 2: Agenda and Voting - The agenda includes proposals to cancel the supervisory board, expand the business scope, amend the company’s articles of association, and elect new board members [2][4]. - A total of 43 shareholders (or their proxies) attended the meeting, representing 49,053,096 voting shares, which is 45.9872% of the total voting shares [5]. Group 3: Voting Results - All proposed resolutions were approved by the shareholders, with significant support for each item, such as 99.9035% approval for the proposal to amend the articles of association [6][10]. - The election of non-independent and independent directors received unanimous support, with no votes against any of the candidates [8][9].

Core Points - The company held its first meeting of the fourth board of directors on June 4, 2025, where all directors unanimously agreed to waive the notice period for the meeting [1] - Chen Yinlong was elected as the chairman of the fourth board of directors, with a unanimous vote of 7 in favor [1] - The board also elected members for various specialized committees, with Chen Yinlong serving as the convener of the strategic committee and other members appointed accordingly [2] - Wu Shujing was appointed as the general manager of the company, with a unanimous vote of 7 in favor [3] - Four individuals, including Chen Yujie and Ye Chunsheng, were appointed as deputy general managers, also with a unanimous vote of 7 in favor [4] - Yu Miaomiao was appointed as the financial officer, receiving unanimous support from the board [4] - Fei Qijun was appointed as the secretary of the board, with unanimous approval [5] - Huang Yufeng was appointed as the securities affairs representative, also with unanimous support from the board [5]

股票代码：688767 证券简称：博拓生物 公告编号：2025-034 杭州博拓生物科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州博拓生物科技股份有限公司（以下简称"公司"或"博拓生物"）于2025年6 月4日召开2025年第二次临时股东会，选举产生的第四届董事会成员，与公司于2025 年5月19日召开的职工代表大会选举的职工代表董事共同组成第四届董事会。同日，公 司召开第四届董事会第一次会议，审议通过了选举公司董事长、各专门委员会委员、 聘任第四届高级管理人员和证券事务代表等相关议案。现将具体情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 5 月 19 日，公司召开职工代表大会选举叶春生先生为公司第四届董事会职 工代表董事。2025 年 6 月 4 日，公司召开 2025 年第二次临时股东会，审议通过了《关 于董事会换届选举暨选举第四届董事会非独立董事的议案》《关于董事会换届选举暨选 举第四届董事会独立董事的 ...